# Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN

> **NCT03085719** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 18 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT03085719
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-06-30
- **Primary completion:** 2022-11-01
- **Final completion:** 2027-10-31
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03085719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03085719, "Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03085719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*